Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb 11;11(4):949.
doi: 10.3390/jcm11040949.

Associations between RNA-Binding Motif Protein 3, Fibroblast Growth Factor 21, and Clinical Outcome in Patients with Stroke

Paulo Ávila-Gómez  1 , María Pérez-Mato  2 , Pablo Hervella  1 , Antonio Dopico-López  1 , Andrés da Silva-Candal  3 , Ana Bugallo-Casal  1 , Sonia López-Amoedo  1 , María Candamo-Lourido  1 , Tomás Sobrino  1 , Ramón Iglesias-Rey  1 , José Castillo  1 , Francisco Campos  1
Affiliations

Associations between RNA-Binding Motif Protein 3, Fibroblast Growth Factor 21, and Clinical Outcome in Patients with Stroke

Paulo Ávila-Gómez et al. J Clin Med. .

Abstract

Background: RNA-binding motif protein 3 (RBM3) is a cold-induced marker of good functional outcome of ischemic stroke that is promising as a protective target. Fibroblast growth factor 21 (FGF21) is an obesity- and temperature-related hormone that upregulates the expression of RBM3, which is beneficial as a recombinant treatment and has been tested under different experimental pathological conditions, including stroke. However, the interaction between RBM3 and FGF21 has not yet been tested for clinical stroke conditions.

Methods: In a sample of 66 stroke patients, we analyzed the associations between the FGF21 and RBM3 serum concentrations on admission and at 72 h, body weight, maximum temperature during the first 24 h, and the outcome of patients at 3 months. We also analyzed their association with biomarkers of obesity (adiponectin and leptin) and inflammation (interleukin-6 (IL-6) and interleukin (IL-10)).

Results: Higher concentrations of FGF21 on admission and RBM3 at 72 h were associated with good outcomes. Serum FGF21 and RBM3 were directly related to body mass index and inversely related to the maximum temperature during the first 24 h. We found a positive association between the FGF21 concentrations in obese patients with leptin and a negative correlation with adiponectin in non-obese participants.

Conclusions: This clinical study demonstrates the association between RBM3 and FGF21 levels and the outcome of stroke patients. Although further investigations are required, these data support the pharmacological induction of RBM3 as a promising protective therapy.

Keywords: FGF21; RBM3; body weight; clinical outcome; stroke; temperature.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Profile level of fibroblast growth factor 21 (FGF21) (a) and RNA-binding motif protein 3 (RBM3) (b) on admission, 72 h and 7 days.
Figure 2
Figure 2
Association between fibroblast growth factor 21(FGF21) on admission and RNA-binding motif protein 3 (RBM3) at 72 h.
Figure 3
Figure 3
Analysis of serum fibroblast growth factor 21 (FGF21) and RNA-binding motif protein 3 (RBM3) and their association with temperature (a,b) and body mass index (BMI) (c,d).
Figure 4
Figure 4
Analysis of serum fibroblast growth factor (FGF21) (a) and RNA-binding motif protein 3 (RBM3) (b) and their associations with the functional outcomes of patients.
Figure 5
Figure 5
Association of fibroblast growth factor 21 (FGF21) and RNA-binding motif protein 3 (RBM3) with obesity and inflammatory biomarkers. (a–c) Association between FGF21 on admission and leptin (a), adiponectin (b), and interleukin-6 (IL-6) (c) concentrations in obese and non-obese participants. (d) Association of the circulating concentrations of RBM3 and interleukin-10 (IL-10) at 72 h with the maximum temperature during the first 24 h.
See this image and copyright information in PMC

References

    1. GBD 2016 Stroke Collaborators Global, regional, and national burden of stroke, 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18:439–458. doi: 10.1016/S1474-4422(19)30034-1. - DOI - PMC - PubMed
    1. Jackson T.C., Kochanek P.M. A New Vision for Therapeutic Hypothermia in the Era of Targeted Temperature Management: A Speculative Synthesis. Ther. Hypothermia Temp. Manag. 2019;9:13–47. doi: 10.1089/ther.2019.0001. - DOI - PMC - PubMed
    1. Campos F., Blanco M., Barral D., Agulla J., Ramos-Cabrer P., Castillo J. Influence of temperature on ischemic brain: Basic and clinical principles. Neurochem. Int. 2012;60:495–505. doi: 10.1016/j.neuint.2012.02.003. - DOI - PubMed
    1. Vieites-Prado A., Iglesias-Rey R., Fernandez-Susavila H., da Silva-Candal A., Rodriguez-Castro E., Grohn O.H., Wellmann S., Sobrino T., Castillo J., Campos F. Protective Effects and Magnetic Resonance Imaging Temperature Mapping of Systemic and Focal Hypothermia in Cerebral Ischemia. Stroke. 2016;47:2386–2396. doi: 10.1161/STROKEAHA.116.014067. - DOI - PubMed
    1. Yenari M.A., Han H.S. Neuroprotective mechanisms of hypothermia in brain ischaemia. Nat. Rev. Neurosci. 2012;13:267–278. doi: 10.1038/nrn3174. - DOI - PubMed

LinkOut - more resources